Back to School: How biopharma can reboot drug development. Access exclusive analysis here

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

FDA approves Regeneron's Dupixent in nasal polyps
FDA approved Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat chronic rhinosinusitis with nasal polyps. Dupixent is the first drug approved for the indication (see "Phase III

Read the full 347 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers